Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018The Cervical Cancer Market is Forecast to Show Slow Growth until 2018
By: Rajesh Gunnam The overall cervical cancer market consists of the cervical cancer prophylactics market and the cervical cancer therapeutics market. The cervical cancer prophylactics market grew at a CAGR of 61.5% from $234.8m in 2006 to $1,598.7m in 2010. The cervical cancer therapeutics market grew at a CAGR of 4.3% from $157.3m in 2005 to $194.5m in 2010. The prophylactics market experienced significant growth in the historic period due to the launch of Gardasil (Human Papillomavirus (HPV) quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) Growth in the cervical cancer therapeutics market is expected to decline in the forecast period until 2018, primarily due to the generic erosion of Hycamtin, the only approved therapeutic treatment option available in the market for advanced and recurrent cervical cancer patients. Its patent expired in the US in 2010 and will expire in Europe in 2011. In Japan, the therapeutics market is expected to show steady growth during the forecast period, attributed to the expected launch of two upcoming FIC molecules. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ • Cervical Cancer Prophylactics Possess a Strong Pipeline The cervical cancer prophylactics market is dominated by two vaccines, Gardasil and Cervarix, which are used as preventive vaccines for certain types of HPV. There is one FIC molecule in the late stage of development, which is expected to increase growth in the prophylactics market due to awareness of cervical cancer vaccination programs. GlobalData’s research indicates that there is high level of unmet need in the cervical cancer therapeutics market and moderate unmet need in the prophylactics cervical cancer market. The cervical cancer prophylactics market is well served by two effective vaccines, leaving a moderate level of unmet need. There is a FIC molecule in the prophylactics pipeline which is expected to provide greater coverage of HPV strains than the currently available vaccines. The therapeutics segment on the other hand has only one approved regimen for patients with late-stage cervical cancer, leaving a high level of unmet need. The approved treatment option has a moderate level of efficacy and a high cost of therapy. GlobalData, the industry analysis specialist, has released its new report, “Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Cervical Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Cervical Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cervical Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number